explore -WSS

explore

author：fashion 2025-10-01 17:20:51 - browse：69878

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

leisure time

WSS

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Test for long Covid? Researchers find new clue in blood samples

Idaho college killings prosecutors challenge defense's grand jury claims

Illumina slashes 2023 revenue projections yet again

Dewpoint Therapeutics lays off staff after losing partnerships

Humana cuts profit projections as Medicare Advantage costs soar

hotspot

explore

knowledge

Supreme Court strikes down use of affirmative action

Patients, digital health players weigh in on FTC's data privacy plan

The cancer drug shortage isn’t new — and neither are the solutions

Schizophrenia gene found to be linked to cells' energy dysfunction

Apple is now the first public company to be valued at $3 trillion

Surge in Apellis stock fueled by confidence in safety of its eye drug

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage today, explained in one chart

Tori Bowie and the unacceptable rates of Black maternal death

Think you might have Covid

leisure time

Humana cuts profit projections as Medicare Advantage costs soar

Indictment alleges Trump's ex

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Humana cuts profit projections as Medicare Advantage costs soar

Elizabeth Holmes banned from government health programs

Surge in Apellis stock fueled by confidence in safety of its eye drug

Wikipedia

hotspot

leisure time

focus